ClinicalTrials.Veeva

Menu

Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation (EMBELLIE)

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Unknown

Conditions

COVID-19
Caregivers

Treatments

Other: Survey

Study type

Observational

Funder types

Other

Identifiers

NCT04376944
RECHMPL20_0261

Details and patient eligibility

About

Use lay language. The Covid-19 pandemic hit France in March 2020 and stage 3 of the epidemic justified the introduction of national and unprecedented containment measures from March 17, 2020. The Montpellier CHU experienced peak hospitalizations of Covid-19 infections in late March. The estimate of the proportion of infected people in Occitania, South of France, for the 11th of May 2020 is 3.1% (95% CI: 1.9-5.9) for the Occitania region, to which Montpellier belongs.

In the context of the Covid-19 epidemic, notably due to the absence of pharmacological or vaccine prophylaxis, barrier measures were of crucial importance, especially for exposed caregivers. These measures include an adaptation of individual behavior, the creation of a so-called "Covid" hospital, the wearing of specific equipment in all departments, the use in the rooms of Covid-19 patients of a gown, an apron, gloves, and a FFP2 type mask in the event of contact and sampling, protocolized and standardized bio-cleaning measures, a reorganization of the premises and the definition of specific circuits.

In view of the second wave of the epidemic, estimating the effectiveness of the barrier measures is of major importance. The investigators therefore propose an evaluation of the effectiveness of these measures, by comparing the serological prevalence of infection among caregivers working directly in COVID units compared to caregivers working in services excluding the management of Covid-19 patients.

Systematic evaluation in COVID-19 units of Sarc-Co-V2 infection will also be assessed, with naso-pharyngeal swabs.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • exposed group: exposed caregivers and agents who worked in COVID units (medicine, resuscitation, screening) until their date of collection. An exposed agent or caregiver is defined by the entrance of rooms with a COVID-19 infection during their professional activity.
  • low or unexposed group: caregivers or agents who have worked in non-COVID units in a non-COVID hospital

Exclusion criteria

  • refusal to participate

Trial design

300 participants in 2 patient groups

Exposed group
Description:
Caregivers and agents working directly in COVID units compared to those living.
Treatment:
Other: Survey
Control group
Description:
caregivers anf agents working in services excluding the management of patients screened positive for Covid-19 infection
Treatment:
Other: Survey

Trial contacts and locations

1

Loading...

Central trial contact

Alain MAKINSON, MCU-PH; Marie Bistoquet, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems